Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma., PMID:39409881
CSPG4-targeting CAR-macrophages inhibit melanoma growth., PMID:38895447
Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy., PMID:38735753
MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance., PMID:37990493
CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate., PMID:37432459
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma., PMID:37208128
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4., PMID:37185332
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen., PMID:36768830
The role of pericytes on the efficacy of bevacizumab in colorectal cancer., PMID:36422502
Generation and Characterization of Native and Sialic Acid-Deficient IgE., PMID:36362241
The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma., PMID:36140259
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy., PMID:36110930
Identification of Novel Retinal Pericyte-Targeting rAAV Vectors Through Directed Evolution., PMID:36018583
Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers., PMID:35891187
Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial., PMID:35580930
A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET., PMID:35239034
Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation., PMID:34942534
Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development., PMID:34862749
In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart., PMID:34513315
A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model., PMID:34318902
Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection., PMID:34145250
Immunoaffinity-Based Isolation of Melanoma Cell-Derived and T Cell-Derived Exosomes from Plasma of Melanoma Patients., PMID:33704724
Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression., PMID:33613873
BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes., PMID:33404293
Oligodendrocyte Lineage Marker Expression in eGFP-GFAP Transgenic Mice., PMID:33346907
Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas., PMID:32599896
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma., PMID:32331483
In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model., PMID:31769737
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027., PMID:31578248
Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B., PMID:31233493
Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance., PMID:31230410
Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma., PMID:31217827
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade., PMID:31128201
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice., PMID:30956944
Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors., PMID:30625226
Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism., PMID:30340601
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins., PMID:29565434
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models., PMID:29561763
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types., PMID:29375561
Resident cell lineages are preserved in pulmonary vascular remodeling., PMID:29359814
Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage., PMID:29196603
Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4., PMID:29036679
Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display., PMID:28981720
Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants., PMID:28842504
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL., PMID:28657611
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy., PMID:28287848
Development and validation of a cell-based fluorescent method for measuring antibody affinity., PMID:28024998
Isolating subpopulations of human epidermal basal cells based on polyclonal serum against trypsin-resistant CSPG4 epitopes., PMID:28011196
Roles of chondroitin sulfate proteoglycan 4 in fibrogenic/adipogenic differentiation in skeletal muscle tissues., PMID:27582000
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand., PMID:27448975
For research use only. Not for human or drug use.
